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1. Introduction 
The pulmonary diseases of obstructive character have high prevalence in the human 
population and has been subject of several clinical and experimental studies in order to seek 
a wider understanding of their pathogeny, physiopathology and, especially, the 
establishment of more rational ways for their treatment. Accordingly, this great effort has 
led to an extraordinary widening in the concepts of obstructive diseases in the last years, 
involving the integration of mechanical factors, inflammatory agents, autonomic regulation 
of airways and environmental aspects. 
The COPD may be understood as a pathologic condition in which a non-reversible and 
limited gas exchange occurs. There are two clinical entities that constitute the COPD: 
chronic bronchitis and emphysema. Within the COPD spectrum, the main characteristic of 
pulmonary emphysema is air flow blockage and progressive dyspnea, arising out of the 
impairment of alveolar walls and increase of air spaces distal to terminal  bronchiole, 
without significant pulmonary fibrosis (Barnes et al., 2003; GOLD, 2009; Oliveira et al., 
2000).  
The oxidative damage to which lungs are submitted to, as well as the inflammation 
occurring as a response to irritant agents, such as those coming from air pollution and 
cigarette smoke, contributes to the induction of the pulmonary degeneration (Lee et al., 
2011). Therefore, it may be concluded that chief characteristic of COPD is the acceleration of 
functional and morphologic loss, with limitation of gas exchanges, resulting in progressive 
dyspnea, disability and premature death.  
Therefore, the development and progression of the pathology are resulting from the 
interaction of genetic and environmental factors (Ribeiro-Paes et al., 2009). About 1-3% of 
cases of emphysema are generated by enzyme α1-antitrypsin deficiency, that characterizes a 
genetic abnormality as an inheritance of autossomal recessive pattern. The other risk factors 
include: age, infections, as well as social and economic factors (Mannino & Buist, 2007).  
Smoking, however, has been established as the major cause related with COPD, resulting for 
active or passive exposure to the cigarette smoke, and corresponds to 15-20% of cases of 
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pulmonary emphysema (Ribeiro-Paes et al., 2009). The cigarette smoke in their gas and 
particle stages has a significant quantity of oxidant substances. A high number of particles 
and oxidant agents are contained in cigarette smoke. Oxidant agents are capable of reducing 
the effect of the anti-protease system through the oxidation of the active site of those 
enzymes and leading to a direct injury to the extracellular matrix (Barnes 2000; Barnes et al., 
2003; Bast et al., 1991; Rufino & Lapa e Silva, 2006). 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD, 2009) has pointed out 
COPD as a serious public health issue. The pathology is considered the fifth largest cause of 
death worldwide, and has 210 million patients, with 80 million already in the moderate 
and/or serious stage of the disease. Estimates put it at the third ranking of cause of death in 
2020 (GOLD, 2009; WHO, 2008). Moreover, faced with the ageing of world population, the 
economic burden of COPD should represent a significant parcel of the future global 
investments in health (Mannino & Buist, 2007).  
Several clinical strategies, associated with the pulmonary rehabilitation techniques have 
contributed to the extension and improvement of the quality of life of emphysema patients. 
Notwithstanding the significant advances resulting from the introduction of new 
therapeutic approaches and rehabilitation, there has not been any efficient form of treatment 
up to now, other than the one in the palliative scope. The surgery treatment entails highly 
complex procedures and, in the specific case of lung transplant, a shortage of donors. By 
taking these aspects into account, experimental models have been proposed, in order to 
advance the knowledge about the physiopathological processes and new therapeutic 
approaches to the pulmonary emphysema (Gross et al., 1965; Hele, 2002; Mahadeva & 
Shapiro, 2002; Martorana et al., 1989; Nikula et al., 2000; Ribeiro-Paes et al., 2009). 
2. Experimental models in COPD 
Experimental models represent an important tool, since they enable the broadening of 
knowledge about COPD physiopathology, besides allowing the application of new 
therapeutic approaches.  
The methodology of papain intratracheal instillation, proposed by Gross and coworkers in 
1965, represented an original model for pulmonary emphysema induction. Starting from the 
proposition of this pioneer methodology, a series of studies were conducted, which led to 
the development of the models of induced pulmonary emphysema by the instillation of 
other proteases. (Pushpakom et al., 1970; Fusco et al., 2002). 
The use of proteolytic enzymes, chiefly of porcine pancreatic elastase (PPE) for the 
generation of DPOC in an animal model is a widely employed methodology for the 
conduction of experimental studies, since it is mainly a simple and fast method and 
produces physiopathological effects similar to the human disease (March, 2000; Shapiro, 
2000). The experimental models of pulmonary emphysema induced by proteases instillation 
have not reproduced precisely the mechanisms of alveolar destruction ensuing the inhaling 
of smoke and other toxic particles, and, therefore, they do not mimic exactly the sequence of 
pathological events that occur in the disease in humans (Cendron, 1007).  
The use of animal models of cigarette-smoke-induced emphysema means seeking an 
accuracy in experimental models to match the human, chiefly with respect to the 
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physiopathological mechanisms involved in the formation of the emphysema. Up to the 
beginning of the 80's decade, the studies involving induced pulmonary emphysema in 
animals by exposure to cigarette smoke were scarce and their reliability questioned (March, 
2000). In 1981, Huber and coworkers proposed a study based on the model of induced 
emphysema through exposure to cigarette smoke. Some achieved results in the study, with 
respect to morphometric and physiological aspects provided the basis for the ensuing 
research. According to the report from the First Siena International Conference on Animal 
Models of COPD held at the University of Siena in 2001, the induced lesions with the use of 
this model are similar to those observed in emphysematous humans, highlighting the 
importance of the stimulus through cigarette smoke in COPD experimental models. (Hele, 
2001).  
At our laboratory, a new apparatus (Figure 1) for induced emphysema through exposure to 
cigarette smoke is under test. The present device has a series of innovations when compared 
to the already existing inhaling models, such as the fact that the animals are contained inside 
acrylic containers making up the device, while in other cages the animals stay freed. 
Another important aspect worth highlighting relates to the smoke, which is pumped inside 
the box. In the device created by our team, the smoke pumped into the box interior comes 
from puffing on the cigarette; therefore, the situation of an active smoking human is 
mimicked. This apparatus is expected to lead to a model which mimics, as close as possible, 
the human pathology and, accordingly, which can be applied to research projects oriented 
to the analysis of physiopathological processes and to the development of new therapies in 
chronic degenerative pulmonary diseases.  
 
Fig. 1. Apparatus created by the team of the Laboratory of Genetics and Cell Therapy – 
GenTe Cel to induce emphysema by cigarette smoke. 
Notwithstanding the challenges involved in some parameters related to the cigarette-smoke-
induced emphysema models, mainly with respect to the age of the animals, exposure time 
and reproducibility difficulty due to the required resources and time, this is a promising 
approach to turning animal models closer to the human, chiefly in relation to the 
physiopathological processes featured in the human pulmonary emphysema (March, 2000).  
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Currently, the creation and use of genetic models is a very important tool for DPOC study, 
since the strains mimic a series of aspects related to the human disease, mainly with respect 
to the α1-antitrypsin deficiency (March, et al., 2000). At present, several mice strains are 
known to have natural or laboratory-induced mutations (gene targeting), which generate 
abnormal conditions in the animal development and are completed with the spontaneous 
arise of DPOC (March, 2000; Shapiro, 2000). Other methodological approaches to 
emphysema induction entail animal models with genetic modifications. Martorana et al. 
(1995), showed the installation and development of pulmonary emphysema in Tight skin 
transgenic mice, which show mutation in the fibrillin-1 gene, a protein related to the elastic 
fibers assembly making up the pulmonary tissue (Kietly, 1998). 
The Table 1 shows some advantagens and disadvantages of the main animal models of 
induction of COPD.  
 
Experimental model 
of COPD 
Advantages Disadvantages References 
 
 
Protease-induced 
Emphysema 
- Simple method, 
easy to apply, quick 
results, high 
reproducibility 
 
- Morphological 
features similar to 
human disease 
- Lack of 
inflammatory 
constituents 
 
 
- Physiological 
process is different 
from human 
 
 
 
March et al. 
(2000) 
 
 
 
Genetic models 
- Reproduction of 
human  pathology, 
mainly in relation to 
deficiency of α1-
antitripsin 
 
- Demonstrate the 
role of proteases in 
the development of 
the disease 
- The aspects of  
pathology are 
reproduced just 
individually 
 
 
 
- Need for further 
studies with respect 
to inflammatory 
mechanisms 
 
 
 
Shapiro (2000) 
 
Fujita and 
Nakanishi (2007) 
 
 
 
Smoke cigarette 
- Reproduction of 
aspects related to the 
inflammatory 
processes of COPD 
 
- Changes in the 
airways similar to the 
human disease 
- Long time to onset 
of symptoms 
 
 
- Time of exposure 
highly variable 
 
 
 
Zheng et al. 
(2009) 
Table 1. Comparison of the main experimental models of COPD. 
Taking into account these aspects, is evident the great importance of experimental models of 
COPD, even though none of them entirely mimic all the features making up the human 
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disease. The use of these models affords the broadening of knowledge, especially related to 
the physiopathology. The achieved results in animal models may be the grounds for the 
development of new therapeutic alternatives with the ensuing impact on the survival and 
improvement of the quality of life of COPD patients.  
3. Stem cells and cell therapy: The rationale for use in the lung 
The employment of cells for treating diseases is an ancient therapeutic practice, which dates 
back to the transfusion of whole blood or platelet concentrate in different acute or chronic 
clinical conditions. The first hematopoietic stem cells (HSC) transplantations were made 
according to the works of Till and Mculloch in 1961, on the response of mice with the bone 
marrow transplanted after lesion by ionizing radiation. Since then, new ranges and 
possibilities of use of other tissues according to the experimental model adopted by the 
authors have arisen. 
The potential of differentiation of stem cells (SC), i.e., the wide range of options of 
commitments available for the cell (Smith, 2006), has aroused a growing and great interest, 
bearing in view the employment in the therapy of several types of degenerative diseases 
and in tissue bioengineering (Atala, 2008). According to The National Institutes of Health 
(NIH), SC can be defined as cells able to divide for indefinite time in vitro and to give origin 
to specialized cells. Melton and Cowan (2004) proposed a working definition of SC: "a clonal 
self-renewable entity which is multipotent and can generate several types of differentiated 
cells." Notwithstanding the concept variation, SC have two basic characteristic aspects: self-
renewal, in order to maintain the pool of undifferentiated cells for tissue replacement, 
remodeling, and repair, as well as the differentiation into at least one mature cell type. These 
inherent properties for SC are afforded through particular asymmetric divisions, where 
undifferentiated cells are originated, or, alternatively, differentiation into specialized cells 
(Figure 2). 
 
Fig. 2. Assimetric SC division. An undifferentiated SC under microenvironment stimulation 
start assimetric divisions producing two distinct daughter cells. One cell, undifferentiated, 
maintain the SC pool. In contrast, the differentiated cell acquires a new mature and 
specialized phenotype.  
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Considering their origin, SC are classified in three general types: embryonic stem cells 
(ESC), germinative stem cells (GSC), and adult or tissue-specific stem cells (ASC). The ESC 
are derived from the inner cell mass of the blastocyst, capable to generate any differentiated 
cellular type of the three primary germ layers (ectoderm, mesoderm and endoderm), as well 
as the GSC originated from the gonadal crest (Geijsen et al., 2004). On the other hand, ASC 
are undifferentiated cells, found in differentiated cell types in a tissue where they can renew 
themselves for long periods of time, and can differentiate to yield specialized cell types of 
the host tissue. By and large, ESC maintains the undifferentiated stage for a long period of 
time without losing their differentiation potential (Draper et al., 2004). Moreover, the ASC 
have a limited number of generations, and at each division there is loss of response to 
differentiation signals (Jiang et al., 2002).  
The knowledge that undifferentiated cells exist in the bone marrow has been verified 
since the 40's decade; by the way, the blood progenitors are the first well characterized 
SC. Both in humans and in animal models, the literature reports consistent data with 
evidence for the existence of stained SC from the bone marrow in lungs after bone 
marrow transplant (Bittmann et al ., 2001; Kotton et al., 2001; Krause et al., 2001; Lama et 
al., 2007; Ribeiro_Paes et al., 2009; Schrepfer et al., 2007; Suratt et al., 2003; Yamada et al., 
2004). At different experimental situations, these and others classical works have shown 
evidence for the migration of SC to the lung and have provided the theoretical reference 
which gives grounds for the idea of employing cell therapy in the regeneration of 
pulmonary tissue.  
The experimental evidence of migration of SC from the bone marrow to the lungs was 
pioneering described in the work of Pereira et al. in 1995. Authors cultured murine cells 
expressing a collagen human gene and injected the expanded mesenchymal precursor cells 
into irradiated mice. The presence of transplanted cells in recipient animals for a period of 
up to 5 months was showed by PCR in situ assay. There was incorporation into the 
pulmonary tissue, where the cells disseminated through the mesenchymal parenchyma and 
could continue the replication process in vivo. Therefore, bone marrow cells can migrate and 
populate the pulmonary tissue and act as precursors of local cells.  
Experimental animal models and clinical trials in regenerative tissue therapy by intravenous 
(IV) SC or BMMC infusion indicate a “pulmonary first-pass effect” as proposed by Fischer et 
al. 2009. The lungs act as a barrier, where administered cells are preferentially attracted and 
retained. Cell size and adhesion receptors of the stem and progenitors cells IV infused can 
determine this effect through pulmonary microvastulature (Fischer et al., 2009). Five 
minutes after labeled MSC IV infusion was verified, in animal model, a significant greater 
bioluminicensce signal in the lungs, in relation to several other organs, such as heart, spleen, 
liver and kidney. Therefore, the mean size of injected cells larger than the caliber of lung 
capillaries provides an efficient and fast cell trapping in lungs (Schrepfer et al., 2007). 
Interesting works found on literature indicate the initial migration and chimerism in lungs 
after cell transplantation. Krause et al. (2001) transplanted male mice cells into females with 
bone marrow depleted by ionizing radiation and tracked the presence of Y chromosome in 
gastrointestinal tract, liver, lung and skin. It was verified co-staining of pneumocytes type II 
and Y chromosome in bronchi and alveoli showed by FISH assay (Y chromosome and 
surfactant B mRNA staining) and immunohistochemistry (anti-cytokeratin antibodies for 
the detection of epithelial cells). However, authors proposed that the significant damage to 
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the lungs, arising out of the radiation, provided high levels of incorporation in the alveolar 
tissue.  
In the same year, Kotton et al. (2001) IV infused Lac-Z stained cells of transgenic mice into 
recipient wild animals, which underwent pulmonary lesion by intratracheal instillation of 
bleomycin. There was typical staining of lac-Z expression (Incubation in medium containing 
X-gal), with statistically significant increase in the animals sustaining lesion with bleomycin. 
The grafted cells showed evidence for morphologic and molecular phenotype of 
pneumocytes type I. So, cultured or fresh aspirates of bone marrow cells can express 
pulmonary markers. Thereby, these cells could represent a potential therapy in extensive 
alveolar degeneration. 
An elegant experimental model of suppression of bone marrow and later lesion with 
bleomycin was elaborated by Rojas et al., (2005). The authors obtained full survival index 
and protective effect in mice which underwent MSC transplantation. The 
immunohistochemistry analysis of the pulmonary tissue of the animals with suppression of 
bone marrow disclosed, when compared to group without suppression, that the 
transplanted cells (GFP+) were present in the organ and in a large number, even 14 days 
after the administration of bleomycin.  
As in the animal models, cell migration and chimerism were also  observed in human 
patients who received, for different reasons, bone marrow allogeneic transplant, as in the 
models of animal studies. Suratt et al. (2003), in a pioneer work, showed pulmonary 
chimerism upon the incorporation of cells with Y chromosome in women receiving HSC 
allogeneic transplant from male donors. Another study, 7 patients who underwent 
pulmonary transplant between (donor and recipient) individuals of opposite sexes showed, 
by means of different assays of histochemistry staining and molecular analysis (RT-PCR), 
the presence of mesenchymal stem cells (MSC) in lungs of recipients with cytogenetic 
expression of the sex of donor. In a period of up to 11 and a half years after the transplant 
was verified donor cells in the recipient patients (Lama et al., 2007). 
Nevertheless, the SC migration to the lungs can be overestimated and, therefore, they are 
allegedly present at a much lower rate with a questionable clinical meaning. So, the 
results obtained and reported have been evaluated more carefully by some authors, who 
challenge the accuracy of the employed detection techniques. For example, after 
transplanting MSC GFP+ in mice which had previously received an LPS intraperitoneal 
injection, Xu et al. (2008) did not find, in the immunohistochemistry analysis of the 
pulmonary tissue conducted 14 days after the transplant, circumstantial evidence for a 
significant presence of cells with positive sign of GFP. However, although the authors did 
not find evidence for an actual integration of MSC to the pulmonary tissue and the 
presence of cells with the pulmonary phenotype, there was demonstration that the SC 
transplant afforded a decrease in the lungs inflammation and edema induced by the LPS. 
There are, accordingly these results, the indication that the action mechanism of cells 
would be mediated by paracrine factors that stimulate tissue regeneration rather than cell 
engraftment into lungs (Huh et al., 2011). 
More recently, Katsha and collaborators (2011) reported a significant improvement resulting 
from the use of MSC from the murine bone marrow for the repair and regeneration of the 
pulmonary parenchyma, in an elastase-induced experimental model of emphysema. The 
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authors suggest in the same study the importance of paracrine factors derived from MSC as 
the regenerative mechanism operating in the pulmonary parenchyma.  
Notwithstanding the diversity of used methodologies, in human patients and animal 
models, has been proposed that ASC from several tissue sources can migrate and populate 
injured areas in the lung. It is propounded that the regenerative property of SC involves 
cellular migration to the site of tissue damage and probable promotion of functional and 
structural organ repair. This mobilization process (homing) is related to liberation of 
chemotactic mediators by injured organ (Chen et al., 2011). 
4. Use of stem cells in chronic obstructive pulmonary disease: Experimental 
basis 
In lungs, affected by chronic inflammation, there is intense production of molecules that 
signal and can recruit SC (endogenous and transplanted) capable of tissue reconstruction 
(Rojas et al., 2005). In this context, the rationale for cell therapy in COPD comprehends the 
ability of SC homing toward injured pulmonary tissue, allowing repair of the lung 
parenchyma and probable clinical efficacy. 
Two groups of Japanese researchers reported in 2004 the first consistent results of 
pulmonary regeneration in an experimental mouse model (C57BL/6 strain) of lesion and 
later infusion of SC from bone marrow. The mice were submitted to lipopolysaccharide 
(LPS) intranasal treatment after irradiation. An experimental group received bone marrow-
derived progenitor cells transplant from transgenic mice donors expressing GFP. There was 
protection of the lungs against the lesion of the emphysematous type in the animals 
transplanted with BMMC. It was also detection of stained cells (endothelial and epithelial) 
only in the recipient animals in which the induced pulmonary lesion (Yamada et al, 2004).  
In a model of elastase-induced pulmonary emphysema, Ishizawa et al. (2004) reported that 
the treatment with retinoic acid or granulocyte colony-stimulating factor (G-CSF) led to the 
alveolar regeneration and the treatment, concurrently with both factors, resulted in an 
additive effect. There was BMC mobilization to injured alveoli by retinoic acid and G-CSF 
besides regeneration process. 
Several authors around the world reported  experimental and interesting results with cell 
therapy  in animal models of COPD. Some of these works are shortly described in the Table 2. 
At our laboratory, several research projects have been directed for the study of morphologic 
and functional pulmonary recovery after the treatment with ASC in mice with 
experimentally-induced COPD. Our model basically consists of the induction of 
emphysema by intranasal instillation of papain or elastase and later treatment with BMMC 
or MSC pool originated from the bone marrow (Figure 3).  
Female mice of the C57BL/6 act as recipients. Transgenic male mice (with C57BL/6 
background), which express the green fluorescent protein (GFP) are used as donors of 
BMMC and MSC for the purpose of cellular tracking and validation of the post transplant 
chimerism.  
The achieved results both in quality and in quantity have shown the regeneration of the 
pulmonary tissue in animals with emphysema and treated with BMMC pool or MSC (Figure 4). 
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Animal COPD induction Stem cell type / 
source 
Therapeutic effects Probable action 
mechanism 
Reference 
Rabbit Elastase BMMC Improves pulmonary 
function, decreases 
airspace enlargement 
- Yuhgetsu et 
al., 2006 
Rat Papain 
Co-60 
MSC / 
bone marrow 
Improves  alveolar 
parameters (mean 
alveoli area and linear 
interval) 
Inhibition of 
the apoptosis of 
alveolar cell 
wall 
Liu et al., 2008 
Rat Cigarette smoke 
for 6 months 
BMC 
MSC 
Conditioned 
medium of 
MSC/bone 
marrow 
Attenuates cigarette 
induced emphysema, 
restores the increased 
Lm, increase 
pulmonary 
microvastulature, 
Paracrine 
effects 
Huh et al., 
2011 
Sheep Elastase MSC/ lung Increases tissue mass, 
lung perfusion, 
cellularity and ECM 
content. 
Paracrine 
effects 
Ingenito et al., 
2011 
Mice Cigarette smoke 
for 6 months 
Human or 
murine MSC / 
cell-free 
contidioned 
medium adipose 
tissue 
Decreases 
inflammation and 
airspace enlargement, 
prevents cigarette-
induced weight loss, 
restores cigarette-
induced BM 
dysfunction 
Paracrine 
effects 
Schweitzer et 
al., 2011 
Mice Elastase MSC / 
bone marrow 
Ameliorates alveolar 
structure, restores 
increased Lm and 
destructive index 
Paracrine 
factors 
Katsha et al., 
2011 
Table 2. Experimental animal models of cell therapy for COPD. 
 
Fig. 3. Experimental design of protease-induced emphysema and ASC treatment. 
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Fig. 4. Pulmonary tissue from female mice C57Bl/6 in representative histological cuts. 
Hematoxylin and eosin staining. Groups: N - no treatment, E - instillation of elastase only, 
ETM - instillation of elastase and MSC transplant and ETH - instillation of elastase and 
infusion of BMMC. Original magnification 200 x. 
The regeneration of the pulmonary tissue, expressed in a quantitative way as the 
measurement of the mean linear intercept (Lm), had a significant statistical difference 
between animals treated with ASC and controls.  
In accordance with the data showed in Figure 5, there is a statistically significant difference 
between E group, treated with elastase only, and N group, with no treatment, which shows 
evidence for the efficacy of elastase via intranasal administration in the induction of 
pulmonary emphysema. Between groups treated only with elastase (E) and treated with 
elastase and growth medium (EME) there is no statistically significant difference, which 
suggests the inability of the infusion vehicle in the regeneration of the pulmonary 
parenchyma. Furthermore, the experimental groups, treated with HSC or MSC have not 
shown statistically significant difference in comparison with N group, with no treatment. It 
is worth noting that groups treated with HSC and MSC have not turned out significant 
difference, which shows the therapeutic equivalence between the two stem strains 
originated from the bone marrow.  
The comparison between the achieved values of Lm equivalent to the groups undergoing 
the elastase instillation (E) and treated with DMEM (EME), as well as the groups with 
experimentally-induced emphysema and treated with HSC or MSC has shown statistically 
significant difference, according to Figure 5 (p>0.05). 
Accordingly, it is possible that MSC and BMMC hold a potential role to deliver the required 
cellular strain diversity during the tissue regeneration process, possibly by paracrine 
mechanisms (Katsha et al, 2011) and to check, in a significant and effective way, the repair of 
the lesion in the pulmonary tissue.  
www.intechopen.com
 Cell Therapy in Chronic Obstructive Pulmonary Disease: State of the Art and Perspectives 
 
465 
 
Fig. 5. Mean linear intercept (Lm) of the animals in the control and treated groups.  
N Group - no treatment, EME - instillation of elastase and infusion of DMEM growth 
medium, ETH - instillation of elastase and infusion of BMMC, E - instillation of elastase 
only, ETM - instillation of elastase and MSC transplant. Medians followed by the same letter 
indicate no significant difference (p>0,05).  
As it can apprehended from the literature, there is a consistent set of results generated by 
several laboratories, including those achieved by our research group, which supplied the 
experimental basis and afforded the cell therapy application by our group in COPD patients. 
5. Clinical application: Cell therapy as a new therapeutic approach for COPD 
Due to the high prevalence and significant economic and social impact caused by COPD, 
there are, as already presented, several researches in cell therapy, described in animal 
models, which sustain the use of ASC in human patients with COPD. 
The results arising out of the basic research in animal models of COPD cell therapy, at our 
laboratory, have shown regeneration of the pulmonary parenchyma both in the qualitative 
and in the quantitative forms, as demonstrated by the histological analyses and by the 
measurement of the Lm. These results were the grounds for the preparation of a research 
project submitted to the National Committee of Ethics in Research (CONEP-Brazil) in April 
2008. The clinical protocol was approved in April 2009 (registration nº 14764, CONEP 
233/2009) and, on May 11th, 2009, the first patient, with CPOD in advanced stage, was 
submitted to BMMC pool  infusion (Ribeiro-Paes et al., 2011).  
This first work corresponds to a phase 1 clinical screening for the evaluation of safety 
concerning SC infusion in COPD patients and it was registered with Clinical Trials – NIH – 
USA (NTC01110252). The experimental outlining consists, basically, of the autologous 
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transplant of Bone Marrow Mononuclear Cells (BMMC) pool in patients with COPD in 
advanced stage, higher than 3 according to the Modified Medical Research Council (MRC) 
Dyspnea Scale Score (Curley, 1997; Mahler & Wells, 1988). The study design is shown in 
Figure 6.  
 
Fig. 6. Clinical protocol adopted for cell therapy in patients with advanced pulmonary 
emphysema (Ribeiro-Paes et al., 2011). 
In the pre-procedure period, the selected patients were submitted to a full pulmonary and 
cardiac evaluation. Routine laboratory tests were also performed and the Dyspnea Scale 
Score test, modified according to the British MRC, was also conducted.The selection criteria 
is presented below. 
Inclusion criteria: 1) age between 40 and 76 years; 2) severe obstructive pulmonary disease; 
3) ineffective clinical treatment; 4) limited life expectancy; 4) limitation in daily physical 
activities; 5) possibility of pulmonary rehabilitation physiotherapy; 6) acceptable nutritional 
condition; 7)  acceptable cardiac function; 8) no tobacco use for at least six months; 9) 
satisfactory psychosocial and emotional profile and family support and 10) Dyspnea Scale 
Score greater than 3. 
Exclusion criteria: 1) active pulmonary or extra-pulmonary infection; 2) serious 
coronaropathy and/or ventricular dysfunction; 3) significant renal illness and/or hepatitis; 
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4) detected immunosuppressive illnesses, including HIV; 5) hepatitis B or C; 6) smoking 
habit; 7) carrier of known neoplasies; 8) pregnancy; 9) noncompliance with established 
medical protocol; 10) psychosocial problems, including drug or alcohol abuse; 11) lack of 
family support. After the selection, the participants received written and verbal information 
explaining the study and written consent was obtained from all participants before the 
beginning of the procedure.  
After a thorough clinical evaluation, bone marrow of the voluntary patients was collected, 
processed and the BMMC pool achieved after isolation in Ficoll density gradient. The 
infusion of the achieved mononuclear fraction was made by peripheral IV (brachial medial) 
way and the clinical evolution of patients after the transplant has been monitored until the 
present date by the conduction of pulmonary function tests. 
The use of BMMC pool for cell therapy in COPD patients has shown to be quite safe. No 
intercurrent disease occurred that could put the research's voluntary subjects in clinically 
serious situations or long lasting discomfort. 
All the voluntary subjects of the research had some kind of clinical improvement. The 
spirometry tests showed a very slight improvement, as shown in Figure 7. The VEF 1 
showed an improvement in all patients after thirty days. 
 
Fig. 7. Spirometry absolute values from 3 research patients included in clinical protocol and 
submitted to autologous BMMC transplantation. 
Likewise, the increase in the CVF and CV parameters occurred in all patients after 30 days 
had lapsed from the procedure (Figure 7). However, after this period, there was a decrease 
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in CVF; in spite of this fact, an important aspect is that the functional parameters remained 
always higher than the ones found before the procedure. 
An interesting information turned out in the long term results, approximately 2 years of 
clinical monitoring. The spirometry parameters along the post transplantation period, by 
and large, maintain a certain regularity and similarity to those found before the procedure. 
One of the research subject disclosed a significant increase in the forced vital capacity, after 1 
year and 3 months of treatment (Figure 8); The analysis of this parameter suggests a 
proximity to normality and reduction of the severity of the disease.  
  
  
Fig. 8. Percentage of predicted and absolute values from a patient spirometry until 1 year 
and 3 months after BMMC autologous transplant.  
The results from this clinical protocol show the procedure should be conducted at an earlier 
stage, that is, at a less advanced stage of the pathology. As mentioned, the laboratorial 
analysis, confirmed by clinical response, has reported a significant improvement in all 
patients, chiefly in the first 30 days after the procedure was carried out. After this period, 
laboratory tests displayed a tendency to decrease; however they did not drop to the base 
values obtained before the BMMC therapy treatment. These results advance the possibility 
that cell therapy may be applied in repeated doses from time to time for the purpose of 
stimulating pulmonary regeneration.  
Another protocol under registration with Clinical Trials (NTC00683722) corresponds to a 
multicenter, double-blind, placebo controlled phase II study for patients with moderate to 
severe COPD. The clinical protocol, sponsored by Osiris Therapeutics Inc. (Columbia, MD), 
concerns the employment of ex vivo cultured adult human SC (PROCHYMAL) in the 
treatment of pulmonary emphysema. The purpose comprehends the evaluation of safety 
and efficacy of MSC multiple infusion.  
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As proposed by Osiris Therapeutics “Preclinical and clinical data suggest that Prochymal’s 
unique mechanism of action may provide a first-in-class treatment option with the ability to 
reverse the underlying disease”. However, there is no publication to date reporting the 
results arising out of the screening made in 62 patients. By virtue of the lack of results from 
the use of PROCHYMAL cell therapy in COPD, it is not possible to check and uphold the 
effect of regression of chronic inflammation in lungs as a response to the MSC treatment. 
Therefore, no critical evaluation may be made about the results of the protocol proposed by 
Osiris Therapeutics.  
More recently, a phase 1 clinical study sponsored by Leiden University Medical Center 
(Leiden, Netherlands) was registered with Clinical Trials.gov (NCT01306513). The clinical 
protocol consists of the autologous transplant of bone-marrow-derived MSC in patients with 
COPD (MRC 3) before the surgery to reduce pulmonary volume. The purpose of the work, 
still in progress, is the evaluation of the cell therapy safety, as well as the feasibility of 
cultivating MSC.  
The results achieved by our group, as well as the registration of clinical protocols concerning 
cellular therapy by other research centers, have led to the opening of new strategies of 
therapeutic investigation. Thus, it is possible to establish ew perspectives in regard to the 
formulation of cell therapy experimental designs which will be surely incorporated into 
future research projects for the purpose of optimizing the clinical effect and the quality of 
life of COPD patients.  
6. Perspectives and challenges 
COPD represents a serious public health problem, which, according to the latest projections 
of the World Health Organization, should gradually change for the worse in the coming 
years, with a great impact on the economy, on a global scale. 
The incorporation of new drugs having more effectiveness and longer effect unquestionably 
has contributed to the improvement in quality of life of the patients; however, up to now, no 
significant change in the natural history of the disease has been achieved. In this context, cell 
therapy turns out as a potentially promising treatment option, which, perhaps, may 
represent a change of paradigm in therapeutics and in the natural course of the disease.  
The results achieved at our laboratory and by several other coworkers, at different research 
centers, have shown a morphological recovery of the pulmonary parenchyma in animals 
with experimentally-induced emphysema by the employment of proteases and/or cigarette 
smoke. From said results, a pioneer treatment with BMMC pool was administered for 
patients with emphysema in advanced stage. It is a project in an initial phase and the sample 
of treated patients is still small, which limit the analyses from the statistical point of view. At 
our research center, a new project will soon start. It will comprehend a larger sample (about 
40 patients) and the employment of a new methodology, which the use of MSC.  
Notwithstanding the statistical limitations, the pioneer publication of the results by our 
research group (Ribeiro-Paes et al., 2011), has afforded the preparation of some logical 
inferences and methodological suggestions which will be incorporated into future projects. 
The use of MSC obtained from adipose tissue has disclosed a highly promising future 
perspective. Furthermore, the feasibility of establishing a protocol with repeated SC 
infusions should also be taken into account, just like in chronic treatments with drugs. 
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There are, finally, a series of questions and possibilities that arise from this pioneering 
studies and results obtained in our laboratory. The sample of treated patients is still small. 
There is, indeed, in these beginnings of research, far more doubts than certainties. Also, 
extreme caution should be exercised so as not to arouse false expectations and unrealistic 
hopes in COPD patients. Only the first trials have been carried out. We do not know exactly 
how this story is going to unfold. However, the first steps of a long and challenging journey 
have been taken, but surely it looks potentially promising, in therapeutic terms. For our 
group, it means a very stimulating journey of research and work.  
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